| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5876444 | The American Journal of Medicine | 2014 | 4 Pages |
Abstract
A single 5 mg zoledronic acid intravenous infusion in patients with osteoporosis secondary to indolent systemic mastocytosis is associated with significant increases in spine and hip bone mineral density and decreases of bone turnover markers over at least 1 year. Yearly zoledronic acid might represent a therapeutic option for indolent systemic mastocytosis-associated osteoporosis.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Maurizio MD, Roberta MD, Ombretta MD, Gaia MD, Luca MD, Marta MD, Giovanni MD, Patrizia MD, Silvano MD, Davide MD,